newsfilter
← Latest News
GlobeNewswire·

Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2